Interviews

A member of our First Report Managed Care Editorial Advisory Board explains why managed care decisions hinge on confidence over speed—and how embedding behavioral science across the care continuum can close adherence gaps, activate patients,...

Lingbin Meng, MD, discusses how adding retifanlimab to chemotherapy may reshape frontline treatment for advanced squamous cell carcinoma of the anal canal.

Dr Benson reviews the epidemiology and unmet clinical need in advanced squamous cell carcinoma of the anal canal (SCAC) and examines the evolving role of immunotherapy in the first-line setting. He also contextualizes recent regulatory and...

In this interview, a guest expert explains why emotional readiness—not motivation or access alone—often determines whether patients can successfully initiate and persist on specialty therapies.

A guest expert explains why specialty drugs dominating US spending is forcing payers to rethink benefit design, oncology strategy, and biosimilar adoption to control costs and improve value.

In this interview, Narjust Florez, MD, discusses how subcutaneous amivantamab from the PALOMA-3 study may improve patient experience, clinic workflow, and treatment adherence while highlighting ongoing unmet needs and real-world...

Corrine Stahura, PharmD, BCOP, discusses how extended dosing intervals and subcutaneous formulations in non–small cell lung cancer are improving patient convenience, reducing infusion center burden, and enhancing operational efficiency while...

Dr Rajat Thawani discusses how biomarker-driven strategies, emerging immunotherapies, and novel delivery approaches are rapidly redefining first-line non-small cell lung cancer (NSCLC) treatment—shifting care beyond traditional chemotherapy...